0
Selected Reports |

Interferon-α Therapy Associated With the Development of Sarcoidosis*

Anthony Pietropaoli, MD; Joseph Modrak, MD; Mark Utell, MD, FCCP
Author and Funding Information

*From the Pulmonary and Critical Care Unit, Department of Medicine, University of Rochester Medical Center, Rochester, NY.

Correspondence to: Anthony P. Pietropaoli, MD, Pulmonary and Critical Care Unit, University of Rochester Medical Center, 601 Elmwood Ave, Box 692, Rochester, NY 14642-8692; e-mail: Anthony Pietropaoli@URMC.rochester.edu



Chest. 1999;116(2):569-572. doi:10.1378/chest.116.2.569
Text Size: A A A
Published online

Interferons (IFNs) have been implicated in the pathogenesis of sarcoidosis. In particular, IFN-γ has been linked to pulmonary macrophage activation, a characteristic feature of sarcoidosis. IFN-α is now being administered therapeutically in a variety of conditions. To date, IFN-α has not been implicated in the pathogenesis of sarcoidosis. We report the case of a 50-year-old woman who developed sarcoidosis while being treated with IFN-α for chronic myelogenous leukemia. Her disease activity correlated with the dosage of IFN-α. We speculate that the immunomodulatory effects of IFN-α triggered clinical manifestations of sarcoidosis in this patient.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Inhaled Interferon and Diffusion Capacity in Idiopathic Pulmonary Fibrosis (IPF). Sarcoidosis Vasc Diffuse Lung Dis 2015;32(1):37-42.
The Value of T-SPOT.TB in Early Diagnosis of Tracheobronchial Tuberculosis. Sarcoidosis Vasc Diffuse Lung Dis 2016;32(4):336-41.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543